insights_auto
Outlook: 53.5% bullish·5.6% bearish
Go to analysischevron_right
AMGN:NASDAQ
Amgen Inc
468,11 $
arrow_upward
+0,62%(+2,88) 1D
471,17 $
arrow_upward
+0,65% (+3,06)bedtimeAfter hours
Closed: 11 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
460,98 $
High
468,46 $
Low
459,14 $
Mkt. cap
253,21 մլրդ
Avg. vol.
2,76 մլն
Volume
2,01 մլն
Dividend
2,15%
Quarterly dividend
2,52 $
Ex-dividend date
21 օգս, 2026 թ.
P/E ratio
27,14
52-wk high
483,99 $
52-wk low
312,53 $
EPS
17,25 $
Beta
0,43
Shares outstanding
540,91 մլն
No. of employees
32 հզր
Open
460,98 $
High
468,46 $
Low
459,14 $
Mkt. cap
253,21 մլրդ
Avg. vol.
2,76 մլն
Volume
2,01 մլն
Dividend
2,15%
Quarterly dividend
2,52 $
Ex-dividend date
21 օգս, 2026 թ.
P/E ratio
27,14
52-wk high
483,99 $
52-wk low
312,53 $
EPS
17,25 $
Beta
0,43
Shares outstanding
540,91 մլն
No. of employees
32 հզր
News stories
From web sources and news partners
CoinMarketCap
·
3 ժամ առաջ
Amgen Inc tokenized stock (xStock) Price History and Historical Data
Investor's Business Daily
·
4 ժամ առաջ
How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever
Yahoo Finance
·
8 ժամ առաջ
Amgen (AMGN) Stock Looks Cheap Based On Future Cash Flow
Reuters
·
9 ժամ առաջ
Amgen's Sjogren's drug cuts disease activity in trial
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31,5 հզր
Founded1980
HeadquartersԹաուզենդ Օուքս, Կալիֆոռնիա, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websiteamgen.com